Psoriasis is a chronic inflammatory skin disorder with a chronic relapsing course. Biologics have revolutionized the treatment of adult psoriasis with higher efficacy and favorable safety profile. Recently, more studies have focused on the use of biologics in pediatric psoriasis, and several biologics have been approved for use therein. This review is divided into two sections: the first part focuses on real-world studies on the use of biologics in pediatric psoriasis and the second part summarizes the findings of other clinical trials related to biologics in pediatric psoriasis. Case reports have been excluded from this review. Several biologics were used for treating pediatric psoriasis and the efficacy is encouraging. According to the studies included in this review, anti-IL-12/23 and anti-IL-17A for treating pediatric psoriasis might have a better efficacy than anti-TNF-α, but more data are needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.16702 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, People's Republic of China.
Generalized Pustular Psoriasis (GPP) is a rare, severe, life-threatening form of psoriasis and often resistant to conventional systemic therapy. It can be induced by deficiency of interleukin (IL)-36 receptor antagonist. Treatment of patients with GPP is often difficult, and there is no consensus on the best options available to date.
View Article and Find Full Text PDFReal-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective review.
J Am Acad Dermatol
January 2025
Dermatology Research Institute, Calgary, Alberta, Canada; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada. Electronic address:
Recalcitrant Pediatric Facial Vitiligo Successfully Treated with Roflumilast Cream 0.3% Once Daily.
J Clin Aesthet Dermatol
January 2025
Dr. Warren and Ms. Sanchez are with Derm Texas in Dallas, Texas.
Vitiligo is an autoimmune disorder that causes melanocyte damage and pigment loss. The clinical presentation of vitiligo consists of patchy areas of lighter skin and results from a loss of functioning melanocytes and may be more visible in darker skin toned patients. Vitiligo affects approximately 2 percent of children and adolescents in the United States, with half of the affected cases undiagnosed.
View Article and Find Full Text PDFAssociated diseases and their effects on disease course in patients with chronic non-bacterial osteomyelitis: retrospective experience from a single center.
Clin Rheumatol
January 2025
Division of Pediatric Rheumatology and Nephrology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkey.
Objective: Chronic non-bacterial osteomyelitis (CNO) is a rare autoinflammatory bone disease associated with other chronic inflammatory diseases such as familial Mediterranean fever (FMF), juvenile idiopathic arthritis (JIA), spondylarthropathies, inflammatory bowel disease (IBD), and pyoderma gangrenosum. We aimed to describe the clinical and follow-up characteristics of patients with CNO and to compare findings between patients with and without comorbidities.
Methods: The clinical records of patients with CNO who were followed up in our pediatric rheumatology clinic between 2018 and 2023 were reviewed.
The modification effect of concentration on the correlation between ambient ozone and psoriasis: a hospital-based time-series study.
Int J Biometeorol
January 2025
Department of Disease Prevention and Control, Daping Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University (Third Military Medical University), Changjiang Branch St, 10#, Yuzhong, Chongqing, 400042, China.
The effects of short-term ambient ozone (O) exposure on health outcomes have received growing concerns, but its effects on psoriasis is still unclear. The purpose of our study was to investigate the effects of short-term exposure to O on psoriasis, and to find out potential modifiers. A hospital-based time-series study with outpatient visit data of psoriasis was performed in Chongqing, the largest metropolitan in Southeast China.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!